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ABSTRACT
Background: Immunosuppressive therapy may impact cancer risk in inflammatory 
bowel disease (IBD). Cancer specific data regarding risk and outcome are scarce and 
data for renal cell carcinoma (RCC) are lacking. We aimed(1) to identify risk factors 
for RCC development in IBD patients (2) to compare RCC characteristics, outcome 
and survival between IBD patients and the general population.
Methods: A PALGA (Dutch Pathology Registry) search was performed to establish 
a case group consisting of all IBD patients with incident RCC in The Netherlands 
(1991–2013). Cases were compared with two separate control groups: (A) with a 
population-based IBD cohort for identification of risk factors (B) with a RCC cohort 
from the general population to compare RCC characteristics and outcomes.
Results: 180 IBD patients with RCC were identified. Pancolitis (OR 1.8–2.5), 
penetrating Crohn’s disease (OR 2.8), IBD related surgery (OR 3.7–4.5), male gender 
(OR 3.2–5.0) and older age at IBD onset (OR 1.0–1.1) were identified as independent 
risk factors for RCC development. IBD patients had a significantly lower age at RCC 
diagnosis (p < 0.001), lower N-stage (p = 0.025), lower M-stage (p = 0.020) and 
underwent more frequently surgical treatment for RCC (p < 0.001) compared to 
the general population. This translated into a better survival (p = 0.026; HR 0.7) 
independent of immunosuppression.
Conclusions: IBD patients with a complex phenotype are at increased risk to 
develop RCC. They are diagnosed with RCC at a younger age and at an earlier disease 
stage compared to the general population. This translates into a better survival 
independent of immunosuppressive or anti-TNFα therapy.
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INTRODUCTION
Inflammatory bowel disease (IBD), including 
ulcerative colitis (UC), Crohn’s disease (CD) and 
indeterminate colitis is a chronic inflammatory disorder of 
the gastrointestinal tract. Patients with this disease have 
an increased risk for both intestinal and various extra-
intestinal malignancies [1, 2]. This risk is mainly attributed 
to two drivers: chronic inflammation and drug-induced 
immunosuppression [3]. Particularly immunosuppressive 
medication such as thiopurines and methotrexate may play 
a role in the development of extra-intestinal malignancies 
by impairing immunosurveillance of tumor cells or 
inducing DNA damage [4–7]. The potential associated 
cancer risk is an important growing concern given the 
need for prolonged immunosuppressive therapy in IBD, 
especially in view of the aging IBD population.
Various extra-intestinal malignancies, such as 
lymphoproliferative disorders and non-melanoma 
skin cancers occur more frequently in IBD patients 
compared to the general population, mainly in those 
using immunosuppression [2, 6, 8–12]. Although only 
limited evidence is available, it has been suggested 
that immunosuppression in IBD patients may increase 
the risk for a variety of solid malignancies, such as 
renal cell carcinoma (RCC). Indeed, RCC occurs more 
frequently in post-transplantation patients exposed to 
immunosuppressive medication [13]. In addition, the risk 
for urinary tract cancers in IBD patients on thiopurines 
seems to be elevated [3].
It is unknown whether and how IBD therapy impacts 
risk of cancer recurrence, outcome and survival. Aggregate 
data failed to demonstrate an effect of immunosuppression 
and anti-TNFα agents on recurrence of any cancer in 
IBD patients [5]. By contrast, cancer specific data on 
recurrence and outcome are scarce. For example, only 
eight case reports of IBD patients with RCC have been 
described and led to speculation on a putative association 
with immunosuppressive therapy [14–19]. As such, more 
data are needed to estimate RCC risk and to guide the 
subsequent individual IBD therapy.
To this end we established a nationwide cohort 
of IBD patients with incident RCC. We had a dual aim: 
(1) to identify risk factors for RCC development, and in 
particular to investigate the impact of IBD therapy on RCC 
development (2) to compare RCC characteristics, outcome 
and survival between IBD patients and the general 
population, including the impact of immunosuppression 
and anti-TNFα agents.
RESULTS
Patient identification
We identified 180 IBD patients who developed 
RCC in 69 of 87 hospital organizations in the Netherlands 
(Figure 1) [20]. Twenty-seven potential cases could not 
be verified and were excluded. To identify risk factors 
for RCC development we established a control group 
of 1800 IBD patients randomly selected from the IBD 
South Limburg Cohort (IBDSL; Case control study A). 
For the comparison of RCC characteristics and outcomes 
we identified a second control group using the Eindoven 
Cancer Registry (ECR). This search yielded 4388 patients 
with RCC in the general population (Case control 
study B).
Risk factors for RCC development - Case control 
study A
Potential clinical and demographic risk factors 
for RCC development were compared univariable 
between IBD cases who developed RCC and IBDSL 
control patients (Table 1). Male gender, Montreal E3 
pancolitis, perianal disease activity, a stricturing and/
or penetrating CD phenotype, and IBD related surgery 
occurred statistically significantly more frequent in the 
case group (p < 0.001 for all comparisons). Furthermore, 
cases had a statistically significantly longer duration of 
follow up since IBD diagnosis (p < 0.001), but used less 
thiopurines (p = 0.047) and anti-TNFα agents (p = 0.006) 
during follow up. We considered differences in inclusion 
period (IBD diagnosis since 1950 (cases) versus IBD 
diagnosis since 1991 (controls)) as a reason for these 
differences, since widespread use of thiopurines and the 
introduction of anti-TNFα therapy occurred in the last 
decade of inclusion. Using similar inclusion periods of 
IBD diagnosis for both cases and controls (since 1991) 
almost abolished treatment differences (5-aminosalicylic 
acids (5-ASA), 89.6% (cases) versus 89.8% (controls), 
p = 0.954; thiopurines, 35.6% versus 40.2%, p = 0.432; 
methotrexate, 0.0% versus 5.3%, p = 0.049; cyclosporine, 
4.1% versus 1.5%, p = 0.102; anti-TNFα therapy, 15.1% 
versus 19.7%, p = 0.326).
A multivariable logistic regression model that took 
the duration of follow up since IBD diagnosis into account 
was made separately for UC and CD patients to identify 
independent risk factors for RCC development. Included 
variables were: gender, age at IBD diagnosis, extend of 
UC and CD, perianal disease activity, CD phenotype 
and IBD related surgery. As prescribed medical therapy 
might be different and/or not reliable in early years of 
inclusion, we did not include these variables in this model. 
Therefore, we performed a sensitivity analysis including 
patients with an IBD diagnosis since 1991 in both the case 
and control group. Medical therapy was included in this 
logistic regression model.
Table 2 shows the final logistic regression models 
after backward elimination of the non-significant 
variables for both UC and CD patients. Patients 
with a more complex phenotype including Montreal 
E3 UC (OR 1.8–2.5, 95% CI 1.0–5.3), penetrating 
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Figure 1: Patient inclusion flowchart. IBD, inflammatory bowel disease; RCC, renal cell carcinoma
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CD (OR 2.8, 95% CI 1.3–5.8) and/or IBD related 
surgery (OR 3.7–4.5, 95% CI 1.6–8.2) were at increased 
risk for RCC development. Furthermore, male gender 
(OR 3.2–5.0, 95% CI 1.7–13.2) and older age at IBD 
diagnosis but not age by itself (OR 1.0–1.1, 95% 
CI 1.0–1.1) were identified as independent risk factors. 
Use of 5-ASA (OR 0.2, 95% CI 0.0–0.7) protected 
against RCC development.
RCC characteristics and survival - Case control 
study B
Univariable comparisons of RCC characteristics 
between IBD cases and the general population are shown 
in Table 3. IBD patients had a statistically significantly 
lower age at RCC diagnosis (p < 0.001), lower N-stage 
(p = 0.025), lower M-stage (p = 0.020) and underwent 
Table 1: Univariable comparison of potential risk factors and confounders between cases (IBD 
patients who developed RCC) and controls (randomly selected IBD patients from IBDSL) for the 
identification of risk factors to develop RCC (case control study A)
Variable IBD and RCC 
cases (n = 180)
IBDSL (n = 1800) Missing values 
(cases/IBDSL)
P-value
Male gender, n (%) 114 (63.3) 837 (46.5) 0 <0.001
Ever smokeda, n (%) 38 (62.3) 421 (62.5) 11/122 0.979
Age at IBD diagnosis(y), median 43 39 3/1 0.106
IBD typeb
 Ulcerative colitis, n (%)
 Crohn’s disease, n (%)
93 (56.4)
72 (43.6)
1004 (55.8)
796 (44.2) 0 0.885
Ulcerative colitis
 Extend
  Proctitis (E1), n (%)
  Left-sided colitis (E2), n (%)
  Pancolitis (E3), n (%)
14 (17.5)
24 (30.0)
42 (52.5)
243 (24.4)
472 (47.5)
279 (28.1)
10/13 <0.001
Crohn’s disease
 Extend
  Ileum (L1), n (%)
  Colon (L2), n (%)
  Ileocolonic (L3), n (%)
 Upper digestive (L4), n (%)
 Perianal disease activity, n (%)
 Phenotype
  Non stricturing/penetrating (B1), n (%)
  Stricturing (B2), n (%)
  Penetrating (B3), n (%)
  Stricturing and penetrating, n (%)
27 (38.6)
19 (27.1)
24 (34.3)
2 (2.8)
21 (30.0)
19 (27.9)
16 (23.5)
15 (22.1)
18 (26.5)
223 (28.1)
183 (23.0)
389 (48.9)
65 (8.2)
119 (14.9)
437 (54.9)
171 (21.5)
96 (12.1)
92 (11.6)
2/1
1/0
2/0
4/0
0.054
0.106
0.001 
<0.001
Medical therapy prior to RCC diagnosis
 5ASA, n (%)
 Thiopurines, n (%)
 Methotrexate, n (%)
 Cyclosporine, n (%)
 Anti-TNFα therapy, n (%)
145 (94.2)
49 (32.0)
3 (2.0)
5 (3.3)
16 (10.5)
1605 (89.8)
717 (40.2)
95 (5.3)
26 (1.1)
350 (19.7)
26/13
27/17
29/10
27/10
28/25
0.083
0.047
0.074
0.091
0.006
IBD related surgery, n (%) 86 (48.0) 508 (28.3) 1/8 <0.001
Calendar year of IBD diagnosis, median 1989 2003 3/1 <0.001
Duration of follow up since IBD diagnosis 
(y), median
19 7 3/30 <0.001
IBD, Inflammatory bowel disease; IBDSL, IBD South Limburg cohort; RCC, renal cell carcinoma.
a:Smoking data were only available for patients with Crohn’s Disease
b:Indeterminate colitis was not considered in this comparison since these patients were excluded from IBDSL
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more frequently surgical treatment for RCC (p < 0.001). 
This may be attributed to a high percentage of incidentally 
diagnosed cancers in the case group (n = 80/180, 51.3%).
Figure 2 displays the overall survival curves of the 
case and control group. IBD patients had a statistically 
significant better overall survival compared to the general 
population (p < 0.001). However, age at RCC diagnosis, 
T-stage, M-stage, surgical treatment and calendar year of 
RCC diagnosis emerged as confounders in a Cox model. 
Adjusted for these confounders, a protective effect of IBD 
on overall survival was still present (p = 0.026; HR 0.7; 
95% CI 0.5–1.0).
RCC survival related to medical IBD therapy
Based on received IBD medication, we performed 
subgroup survival analysis for IBD cases with RCC. 
Patients who used immunosuppression (including 
thiopurines, methotrexate and cyclosporine) and/or 
anti-TNFα therapy before or after RCC diagnosis had 
a statistically significantly better disease free survival 
following RCC diagnosis compared to those who did 
not (Figure 3). Especially patients who were treated 
with immunosuppression and/or anti-TNFα agents after 
RCC diagnosis, showed a better disease free survival. 
However, a multivariable Cox analyses adjusted for 
the confounders TNM stage and age at RCC diagnosis, 
abolished this protective effect of immunosuppressive 
and anti-TNFα therapy (immunosuppression before 
RCC diagnosis, p = 0.946; immunosuppression 
after RCC diagnosis, p = 0.386; anti-TNFα therapy before 
RCC diagnosis, p = 0.673; anti-TNFα therapy after RCC 
diagnosis, p = 0.502). Similar survival curves were found 
for the effect of IBD therapy on overall survival (data not 
shown).
Following a similar strategy as for the identification 
of risk factors we performed a sensitivity analysis 
focusing on patients who carried an IBD diagnosis since 
1991. We determined the effect of medical therapy on 
disease free and overall survival. All survival analyses 
and Cox models showed similar results as shown above 
(data not shown).
DISCUSSION
One of the key findings of our study is that IBD 
patients with a complex phenotype (including Montreal 
E3 UC, penetrating CD and/or IBD related surgery) are 
at increased risk to develop RCC. They are younger at 
diagnosis and carry a lower RCC stage compared to the 
general population. This translates into a better disease 
free and overall survival. The second key finding of our 
study is that immunosuppressive and anti-TNFα therapy 
does not adversely affect disease free and overall survival 
in IBD patients following RCC diagnosis.
A better survival in our IBD cohort with RCC 
may be caused by frequent abdominal imaging in these 
patients, which leads to incidental findings such as 
RCC. Due to the widespread use of imaging techniques, 
the incidental detection of RCC in the general 
population significantly increased in recent decades to 
approximately 40% [21–23]. This compares to 51% for 
incidentally detected RCC in our IBD cohort. Previous 
studies have shown that patients with these incidentally 
detected RCC are diagnosed at an earlier stage, which 
is translated into a better survival after correction 
Table 2: Final multivariable regression model for the identification of independent risk factors to 
develop RCC
Model Variable Coefficient β Odds ratio (95% 
confidence interval)
P-value
Ulcerative colitis (all cases, n = 1061) Male gender
IBD related surgery
Age at IBD diagnosis
Montreal E3 colitisa
1.169
1.499
0.023
0.598
3.218 (1.715–6.040)
4.477 (2.433–8.238)
1.023 (1.006–1.042)
1.818 (1.045–3.163)
<0.001
<0.001
0.009
0.034
Ulcerative colitis (sensitivity analysis, n = 1015) Male gender
IBD related surgery
Age at IBD diagnosis
Montreal E3 colitisa
5-ASA
1.609
1.306
0.028
0.922
–1.746
4.999 (1.889–13.226)
3.692 (1.578–8.641)
1.029 (1.006–1.051)
2.513 (1.2005.262)
0.174 (0.044–0.687)
0.001
0.003
0.011
0.015
0.013
Crohn’s disease (all cases, n = 845) Age at IBD diagnosis
Penetrating disease
0.035
1.021
1.035 (1.014–1.057)
2.776 (1.320–5.836)
0.001
0.007
Crohn’s disease (sensitivity analysis, n = 811) Age at IBD diagnosis 0.049 1.051 (1.028–1.074) <0.001
Similar inclusion periods of IBD diagnosis (since 1991) for cases and controls were used in the sensitivity analysis (case 
control study A). IBD, inflammatory bowel disease; 5-ASA, 5-aminosalicylic acids.
aReference category is patients with Montreal E1 or E2 colitis
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Figure 2: Overall survival curves of the general and IBD population following RCC diagnosis. IBD, inflammatory bowel 
disease; ECR, Eindhoven cancer registry
Table 3: Univariable comparison of RCC characteristics between cases (IBD patients who 
developed RCC) and controls (RCC patients in the general population derived from ECR) (case 
control study B)
Variable IBD and RCC cases 
(n = 180)
ECR (n = 4388) Missing values(cases/
ECR)
P-value
Male gender, n (%) 114 (63.3) 2659 (60.6) 0 0.461
Age at RCC diagnosis 
(y), median
62 (27–83) 66 0 <0.001
Location
 Left-sided, n (%)
 Right-sided, n (%)
89 (50.6)
87 (49.4)
2119 (48.7)
2230 (51.3) 4/39 0.631
Grade
 1–2, n (%)
 3–4, n (%)
88 (72.7)
33 (27.3)
1214 (69.3)
539 (30.7) 59/2635 0.442
T stage
 T1–T2, n (%)
 T3–T4, n (%)
130 (76.9)
39 (23.1)
2509 (70.9)
1032 (29.1) 11/847 0.089
N stage
 N0, n (%)
 N+, n (%)
160 (94.1)
10 (5.9)
3281 (88.6)
423 (11.4) 10/684 0.025
M stage
 M0, n (%)
 M1, n (%)
155 (87.1)
23 (12.9)
2962 (80.0)
742 (20.0) 2/684 0.020
Surgery, n (%) 168 (93.9) 3318 (75.6) 1/0 <0.001
Calendar year of 
RCC diagnosis, 
median
2003 2007 0 <0.001
RCC, renal cell carcinoma; IBD, inflammatory bowel disease; ECR, Eindhoven cancer registry.
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for confounders (TNM stage, age at RCC diagnosis, 
calendar year) [22, 24]. This is in line with our study 
in which IBD patients (including a high proportion of 
incidentally diagnosed cancers) received earlier RCC 
diagnosis and had a better survival.
We found that patients with a more complex IBD 
phenotype are at increased risk to develop RCC. A more 
frequent and intensive use of the health care system, 
including abdominal imaging, may be associated with 
this phenomenon. Indeed, another study found that 
IBD patients exposed to anti-TNFα agents (generally 
prescribed for patients with a more complex IBD 
phenotype) developed RCC at a younger age and 
received earlier RCC surgery compared to IBD patients 
unexposed to anti-TNFα therapy or patients having 
rheumatoid arthritis [25]. Other risk factors for RCC 
development were male gender and older age at IBD 
onset (not age by itself), but not the use of medical 
therapy. One could hypothesize that with increasing 
age, potential cancer risk factors accumulate until IBD 
onset with subsequently accelerated carcinogenesis. 
As such, patients who develop IBD later in life are at 
increased risk to develop early colorectal cancer (<8 y) 
and more widespread colorectal neoplasia [26, 27]. The 
Figure 3: Disease free survival curves in IBD subgroups with RCC based on IBD medication received. RCC, renal cell 
carcinoma
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role of immunosuppression and/or anti-TNFα agents in 
relation to cancer development remains to be clarified 
as the literature reports contradictory results [3, 5, 28].
Results of our study demonstrated no adverse 
effect of immunosuppression and/or anti-TNFα therapy 
on both disease free and overall survival following 
RCC. These therapies were mainly (re)started or 
continued after RCC diagnosis in patients with low 
stage RCC and as a corollary these patients showed 
a better disease free and overall survival (Figure 3). 
For example, 32 out of 41 patients (82.1%) who used 
immunosuppressive therapy and 17 out of 21 patients 
(81.0%) with anti-TNFα therapy after RCC diagnosis 
had a T1 RCC. Adjustment for TNM stage abolished 
the protective effect of immunosuppressive and anti-
TNFα therapy and no differences on survival were 
subsequently found. These findings are in line with the 
only available, prospective study in IBD patients, which 
showed no negative impact of immunosuppressive 
agents on recurrent cancer of any type [5]. Other data 
originates from observational studies including patients 
with rheumatoid arthritis or solid organ transplants. No 
difference in any new or recurrent malignancy incidence 
was observed in rheumatoid arthritis patients exposed 
or unexposed to anti-TNFα agents [7, 29]. A study in 
post-transplant setting demonstrated a recurrence rate 
of 0% for incidentally diagnosed RCC and of 30% for 
symptomatic RCC, although a formal comparison to a 
control group was lacking [30].
Despite concerns regarding a cancer inducing 
effect of anti-TNFα therapy, TNFα blockers have been 
previously considered as a therapeutic strategy for RCC 
[31, 32]. Previous studies showed that TNFα can act as 
an autocrine tumor growth factor and that its presence is 
associated with poor prognosis. Indeed, phase I/II trials 
in RCC demonstrated an anti-tumor effect of anti-TNFα 
treatment [32]. However, the most recent phase II trial in 
2010 showed no beneficial effect of anti-TNFα therapy in 
metastatic RCC [31]. Similarly, results of our study did 
not show a better survival of metastatic RCC in patients 
treated with anti-TNFα agents (data not shown).
Our study has important clinical implications 
for the evidence-based management of IBD therapy in 
patients with a history of RCC. As no adverse effect of 
IBD therapy on disease free and overall survival was 
observed, our data suggest that these agents could be 
considered following RCC. Cancer specific data are 
lacking to date, although case-by-case management is 
encouraged based on the characteristics and expected 
evolution of the cancer, the probable impact of IBD 
therapy on cancer evolution, and IBD severity [4, 7]. 
The impact of dose, duration and time interval following 
RCC remains to be assessed in larger prospectively 
followed cohorts. In addition, more cancer specific 
data are needed for other types of cancer to develop 
individualized evidence-based management strategies 
in IBD patients with cancer.
The present study has several limitations. First, 
the retrospective nature of data collection could 
have influenced the completeness and accuracy of 
the extracted data. For example, medication use was 
difficult to ascertain from older medical records. To 
address this issue, we performed sensitivity analyses 
including patients with similar calendar years of IBD 
diagnosis or RCC diagnosis in the case and control 
group, disseminating missing values and errors across 
groups. Second, the use of multiple databases and 
registries resulted in different ways of data collection 
and the absence of some variables. For example, 
potential risk factors and confounders, such as smoking 
behavior, hypertension, body mass index and incidental 
detection of RCC, were not available in IBDSL or the 
ECR. Given this limitation some of our results need to 
be interpreted with caution. However, it was inevitable to 
use multiple databases to address our research questions. 
Finally, selection bias may have been introduced as we 
used different registries and databases. For example, 
cases were identified nationwide whereas controls with 
RCC and controls with IBD were ascertained from two 
different registries in the south of The Netherlands. 
However, previous studies confirmed that these 
population-based registries are representative of the total 
Dutch population [33].
In conclusion, we identified a complex IBD 
phenotype as a risk factor to develop RCC. IBD patients 
were diagnosed with RCC at a younger age and at an 
earlier disease stage compared to the general population, 
which translated into a better disease free and overall 
survival following RCC. Immunosuppressive and anti-
TNFα therapy did not adversely affect this better survival. 
This observation may aid physicians in guiding IBD 
therapy following RCC diagnosis and treatment.
MATERIALS AND METHODS
Study design and data sources
In order to study risk factors and the clinical course 
of RCC in IBD patients, we performed two retrospective 
nationwide case control studies. We established a case 
group consisting of all IBD patients who developed 
RCC in The Netherlands assembled over 22 years, using 
PALGA (Dutch nationwide network and registry of histo- 
and cytopathology) [34]. Subsequently, these cases were 
included in the following two case control studies:
A. The first case control study aimed for the 
identification of risk factors to develop RCC. Controls 
were randomly sampled from IBDSL, a population-based 
IBD registry [35].
B. The second case control study was performed 
to compare RCC characteristics and outcomes between 
IBD patients and the general population. Controls were 
identified from the ECR and included patients from the 
general population who developed RCC [36].
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The study was approved by the Privacy Commission 
and Scientific Council of PALGA and by the Medical 
Ethics Review Committee region Arnhem - Nijmegen 
(Registration number 2013/419).
Case identification
PALGA was searched in order to identify all IBD 
patients with concomitant RCC in The Netherlands from 
January 1991 until May 2013. The PALGA registry 
contains pathology reports generated in the Netherlands 
since 1971 and has complete national coverage since 
1991 encompassing all pathology laboratories from all 
academic and non-academic hospitals in the Netherlands 
[34]. We performed a PALGA search with the following 
search terms: “ulcerative colitis”, “Crohn’s disease”, 
“indeterminate colitis”, or “chronic idiopathic 
inflammatory bowel disease” combined with all “primary 
carcinomas of the kidney” or “metastasis of kidney 
cancer”. Cases were further confirmed or excluded after 
careful evaluation of the individual pathology reports and/
or medical records (Figure 1).
All patients with UC, CD or indeterminate colitis 
who developed a histologically confirmed RCC following 
IBD diagnoses were included. The diagnosis of IBD 
was based on a combination of clinical, endoscopic, 
histological and radiographic criteria [37]. The following 
exclusion criteria were used: no diagnosis of IBD, no 
diagnosis of RCC, RCC diagnosis before IBD diagnosis 
and RCC diagnosis before 1991.
Controls (A) – IBD South limburg cohort
Controls for the identification of risk factors to 
develop RCC were randomly selected from IBDSL. 
IBDSL is a prospectively followed, population-based IBD 
registry in an area in the southeast of The Netherlands 
between Germany and Belgium, called South-Limburg. 
This area has a population of approximately 645.000 
inhabitants with a low migration rate and covers one 
academic and two general district hospitals [38]. Adult 
patients in this area with a diagnosis of UC or CD 
based on a combination of endoscopic, radiologic and 
histological evidence are included in this cohort since 
1991 [38]. It includes 2807 IBD patients (40.9% CD, 
59.0% UC), which represents 93% of the regional IBD 
population [35]. We randomly included patients with an 
IBD diagnosis between 1991 and 2011. An unmatched 
study design was chosen given the relatively large number 
of cases, allowing adjustment for possible confounders as 
well as to avoid missing potential risk factors [39].
Controls (B) – Eindhoven cancer registry
Controls to compare RCC characteristics and 
outcomes were identified from the ECR, maintained by 
the Netherlands Comprehensive Cancer Organization. The 
registry prospectively collects data on all newly diagnosed 
cancers in the southern part of The Netherlands since 1955 
[36]. This area includes 10 general hospitals and 6 regional 
pathology laboratories, comprising approximately 
2.3 million inhabitants (15% of the Dutch population) 
[40]. Tumor characteristics and patient characteristics 
are routinely extracted from medical records by specially 
trained administrators of the cancer registry. By means 
of an independent case ascertainment method, the 
completeness of the registration is estimated to exceed 
95%. [41] We included all patients with a histologically 
confirmed RCC between 1991 and 2010 from the ECR 
as controls.
Data extraction
Two authors (L.D and L.N) extracted demographic 
and clinical variables from anonymized medical records 
for patients included in the case group. Extracted data 
included gender, date of birth, smoking history (ever/
never), primary sclerosing cholangitis, IBD characteristics 
and RCC characteristics. We collected the following IBD 
characteristics: type of IBD, date of diagnosis, phenotype 
according to the Montreal Classification, and medical 
and surgical treatment. Exposure to 5-ASA, thiopurines, 
anti-TNFα agents, cyclosporine or methotrexate was 
defined as “used” or “not used” since dosage/duration 
could not be reliably retrieved for all cases. RCC 
characteristics included: date of diagnosis, location, tumor 
stage according to the TNM classification (7th edition), 
differentiation grade according to Fuhrman [42], whether 
the tumor was incidentally detected or not, treatment, 
outcome and survival.
Incidentally diagnosed cancers were considered to 
be tumors discovered during investigations performed for 
reasons other than for RCC related symptoms including 
palpable tumor, haematuria (both macroscopic and 
microscopic), flank pain and signs of cachexia related 
to the disease [21]. RCC outcome included disease free 
survival (duration since RCC diagnosis until recurrence 
or death) and overall survival (duration since RCC 
diagnosis until death). Histopathological subtype could 
not be obtained reliably due to the great variability of 
morphology reporting standards since 1991.
Similar variables with corresponding definitions 
were extracted from registries (IBDSL and ECR) for 
patients included in the control groups.
Statistics
For both case control studies we compared potential 
risk factors, RCC characteristics and/or outcomes between 
cases and controls with a univariable analysis. X2 test 
or Fisher exact test (if expected cell counts were < 5) 
were used for categorical data and independent Student 
t test (if normally distributed) or Mann-Whitney U test 
(if not normally distributed) were used for continuous 
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data. Variables with a P-value of < 0.1 in univariable 
analyses were included in a multivariable model. As the 
control group in a case control study should reflect the 
entire source population that gave rise to the cases, we did 
not exclude IBD patients who developed RCC from the 
control groups [43]. These patients were in both models 
analyzed as cases.
For case control study A, identifying independent 
risk factors to develop RCC, we performed a multivariable 
logistic regression model with backward sampling. This 
model was adjusted for the duration of follow up (fixed 
variable), which was defined as the time since IBD onset 
until the date of RCC diagnosis (cases) or the end of 
follow up or death (controls). For case control study B, 
comparing RCC outcome between IBD cases and the 
general population, we made Kaplan Meier survival 
curves and performed log rank analysis. Subsequently 
confounder correction was performed with Cox regression 
model with forward sampling. A covariate was considered 
as a confounder when the beta coefficient of the variable 
of interest (IBD yes/no) changed by 10% or more [44].
A P-value of < 0.05 (2 sided) was considered 
to be statistically significant. All missing values were 
considered to be at random and were excluded from 
analyses. All statistical analyses were performed with IBM 
SPSS statistics version 20.0 (SPSS Inc, Chicago, IL).
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